Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms

 
• By Jessica Merrill
  
flashing light
Pfizer's Xeljanz shows safety issues in a new study • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immunological

More from Therapeutic Category